Bml Capital Management, LLC Adverum Biotechnologies, Inc. Transaction History

Bml Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 30, 2024	BUY	$0.75 - $1.26 $479,439 - $805,457	639,252 Added 16.33%	4,554,252 $3.43 Billion
Q3 2023 Oct 23, 2023	SELL	$1.5 - $2.33 $1.86 Million - $2.89 Million	-1,242,179 Reduced 24.09%	3,915,000 $5.87 Billion
Q2 2023 Jul 24, 2023	SELL	$0.68 - $1.59 $1.3 Million - $3.04 Million	-1,910,000 Reduced 27.03%	5,157,179 $8.2 Billion
Q4 2022 Feb 13, 2023	BUY	$0.54 - $10.3 $3.82 Million - $72.8 Million	7,067,179 New	7,067,179 $4.1 Billion

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $681M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Bml Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bml Capital Management, LLC with notifications on news.